These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38125744)

  • 1. Prognostic value of obesity in patients with cancer treated with immune checkpoint inhibitors: An updated meta‑analysis and systematic review.
    Guo H; Lin XY; Feng S; Wang C; Yuan LQ; Sheng XG; Li DP
    Mol Clin Oncol; 2024 Jan; 20(1):5. PubMed ID: 38125744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    An Y; Wu Z; Wang N; Yang Z; Li Y; Xu B; Sun M
    J Transl Med; 2020 Jun; 18(1):235. PubMed ID: 32532255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis.
    Takemura K; Yonekura S; Downey LE; Evangelopoulos D; Heng DYC
    Eur Urol Open Sci; 2022 May; 39():62-71. PubMed ID: 35528786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis.
    Esposito A; Marra A; Bagnardi V; Frassoni S; Morganti S; Viale G; Zagami P; Varano GM; Buccimazza G; Orsi F; Venetis K; Mazzarella L; Viale G; Fusco N; Criscitiello C; Curigliano G
    Eur J Cancer; 2021 Mar; 145():197-209. PubMed ID: 33493979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients.
    Xu H; Cao D; He A; Ge W
    Int Immunopharmacol; 2019 Sep; 74():105745. PubMed ID: 31302449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
    Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
    Ahmed M; von Itzstein MS; Sheffield T; Khan S; Fattah F; Park JY; Popat V; Saltarski JM; Gloria-McCutchen Y; Hsiehchen D; Ostmeyer J; Khan SA; Sultana N; Xie Y; Li QZ; Wakeland EK; Gerber DE
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34127546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Zhang T; Li S; Chang J; Qin Y; Li C
    BMC Cancer; 2023 Oct; 23(1):1023. PubMed ID: 37872469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy - A systematic review and meta-analysis.
    Trinkner P; Günther S; Monsef I; Kerschbaum E; von Bergwelt-Baildon M; Cordas Dos Santos DM; Theurich S
    Eur J Cancer; 2023 May; 184():151-171. PubMed ID: 36931074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The obesity paradox in patients with colorectal cancer: a systematic review and meta-analysis.
    Li Y; Li C; Wu G; Yang W; Wang X; Duan L; Niu L; Chen J; Zhang Y; Zhou W; Liu J; Hong L; Fan D
    Nutr Rev; 2022 Jun; 80(7):1755-1768. PubMed ID: 35182150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and immune-checkpoint inhibitors in advanced melanoma: A meta-analysis of survival outcomes from clinical studies.
    Roccuzzo G; Moirano G; Fava P; Maule M; Ribero S; Quaglino P
    Semin Cancer Biol; 2023 Jun; 91():27-34. PubMed ID: 36871633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
    Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data.
    Nie RC; Chen GM; Wang Y; Yuan SQ; Zhou J; Duan JL; Liu WW; Chen S; Cai MY; Li YF
    J Immunother; 2021 Nov-Dec 01; 44(9):371-375. PubMed ID: 34456293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.